Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement

Eledon Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.34

Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.
Cash, cash equivalents & short-term investments $42.9M at quarter end, excluding $50M private placement.
Completed oversubscribed $50M private placement at $2.37/share with institutional investors.
First patient dosed in investigator-led islet cell transplant trial with tegoprubart for type 1 diabetes.
Phase 2 BESTOW trial (tegoprubart vs tacrolimus) enrolled 12th participant; full enrollment expected end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.

Period: the quarter ended March 31, 2024
Net income: net loss of $10.3 million
EPS: $0.34 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.